London, UK, 5 August 2013: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical…
Browsing: Sativex
GW Pharmaceuticals, the biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced…
GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid…
From 10th April, Sativex will become a Schedule 4 Part I drug and its continued availability for use in healthcare…
Sarah Martin the British representative for the International Association for Cannabinoid Medicines talks about Sativex and how it helps treat…
Under strict conditions severely ill Germans may be allowed to grow cannabis at home, the Supreme Administrative Court of Munster…
